Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

dition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval, including with respect to TREANDA; manufacturing development and capabilities; market prospects for its products, including with respect to AMRIX; sales, adjusted net income and basic adjusted income per common share guidance for 2007 and 2008; and other statements regarding matters that are not historical facts, including the Company's position and expected performance in 2007 and 2008, the final resolution or outcome of the ongoing investigations by the U.S. Attorney's Office and the Office of the Connecticut Attorney General and the final amount of any settlement and/or fines related thereto, and the relative strength of the foundation for the Company's ongoing compliance efforts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermo
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15 septembre 2014 La deuxième édition ... (semaine internationale sur la sensibilisation au plasma) ... conjointe de la Plasma Protein Therapeutics Association ... , l,IPAW vise à : , ... la collecte du plasma-aphérèse , Reconnaître la ...
(Date:9/15/2014)... ANNAPOLIS, Md. , Sept. 15, 2014  The ... will be celebrated October 12-18. A joint initiative of ... its member companies , IPAW is designed to: ... collection , Recognize the contributions of plasma donors ... about lifesaving plasma protein therapies and rare diseases ...
(Date:9/14/2014)... UMBC’s Biotechnology Graduate Programs’ Virtual Information ... from 12:00 to 1:00 p.m. EDT. The session will ... practice-oriented instruction, designed for working professionals. Participants will also ... career in the biotechnology industry. , If interested in ... UMBC’s Biotechnology Graduate Programs, UMBC offers a variety of ...
(Date:9/14/2014)... particularly ingenious when it comes to survival strategies. They ... hostile environment, for example during treatment with antibiotics. A ... a protective slime capsule consisting of sugar chains and ... have for the first time created a detailed three-dimensional ... blocks cross the bacterial cell wall, a crucial step ...
Breaking Biology Technology:L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2New insights in survival strategies of bacteria 2
... , , BOULDER, Colo. and THOUSAND OAKS, Calif., Dec. 14 ... AMGN ) today announced that they entered into an agreement ... including ARRY-403, currently being tested in a Phase 1 clinical trial ... terms of the agreement, Array will receive an upfront payment of ...
... , , JUPITER, Fla., Dec. ... today that it has extended its collaboration with The Scripps ... to re-annotate the genome of Dyadic,s patented and proprietary C1 ... successful relationship between the two organizations which began in March ...
... , ROCKAWAY, N.J., Dec. 14 ... Evidence-Based Approach , published by the Infusion ... anthracycline extravasation.(1) Anthracyclines are a group of chemotherapy medications ... in the treatment of various types of cancer since the ...
Cached Biology Technology:Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5
(Date:9/15/2014)... hearing and cognitive function may play roles in one,s ... rhythm, pitch, timbre, tone durations, and formal structure in ... article explain that extremes in musical aptitude (extreme capacity/no ... of individuals having moderate aptitude. , "This is a ... underlying genes, and it is influenced to varying degrees ...
(Date:9/15/2014)... the subsequent rapid decrease in the water level of ... square kilometres of new, fertile land in eastern Finland. ... researchers has studied the role that the decrease in ... and humans. After dramatic shifts in the waterways, human ... rise to a new, innovative culture. This stemmed from ...
(Date:9/15/2014)... Sharks, swamps and a tropical rainforest teeming with life ... Yorkshire, England. But for the first time evidence of Doncaster,s ... discovered in a derelict mining tip. , Some of the ... and as well as the egg case, several horseshoe crabs ... All had been preserved in rocks that formed within ...
Breaking Biology News(10 mins):The creation of the Vuoksi River preceded a significant cultural shift 2'Jaws' lived in Doncaster 2
... its wood and cottony fibers, the kapok tree now ... for decades: the notion that African and South American ... million years ago. , Research by University of Michigan ... perhaps other rainforest--trees colonized Africa after the continents split ...
... modification to successfully manipulate the growth in height of trees, ... similar to normal trees – but after several years of ... few inches. , This is a “proof of concept” that ... It opens the door to a wide variety of new ...
... that will be published online in advance of its July ... colleagues (The Salk Institute and HHMI) demonstrate that endosomes can ... animals. , "These findings will influence our thinking of the ... why cells use them as signaling compartments," noted lead author ...
Cached Biology News:The kapok connection -- Study explains rainforest similarities 2Researchers demonstrate way to control tree height 2Researchers demonstrate way to control tree height 3
... for use as a wash buffer for Michels ... is useful for transportation of specimens (such as ... Samples may remain in Transport Fluid for ... Michels Transport Fluid is not a fixative and ...
... use with 96- or 384-well PCR plates Dimples ... location on 96-tube plates End tabs on Thermo-Mat™ ... plate* Efficient sealing is achieved with either Thermo-Mat™ ... or clip-down hot lid thermal cyclers Fully autoclavable ...
... TUNEL-based assay kit provides complete components including ... detection of DNA fragmentation in cultured cells ... in the procedure provides greater sensitivity than ... analyzed by flow cytometry. The kit works ...
... Buffer is a unique alternative to ... (TRIS acetate-EDTA) electrophoresis buffers. Bionic Buffer ... rapid running times, and high-resolution band ... gel electrophoresis after dilution to working ...
Biology Products: